RxDoctor Payments DataLook up a doctor →

Christopher Pendola, MD

Neurology · Kingsport, TNNPI 1013018431

Payments from drug & device makers

$344,071in general payments, 2019–2025

Across 730 payments — averaging $471.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$245K
  • Teva Pharmaceuticals USA, Inc.$39K
  • Sanofi$35K
  • Lundbeck LLC$23K
  • UCB, Inc.$786
  • Biohaven Pharmaceuticals, Inc.$133
  • plus $910 from 29 others

What the payments were for

  • Consulting fees$10,2953%
  • Speaking & faculty fees$317,15492%
  • Travel & lodging$7,4002%
  • Food & beverage$9,0433%
  • Education$1800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$344,071 in reported general payments places this provider in the 90th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$92,390
Medicare patients
361
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide51$169,288
BotoxOnabotulinumtoxina105$136,562
UbrelvyUbrogepant77$107,379
Avonex Pen (4 Pack)Interferon Beta-1a13$104,473
Kesimpta PenOfatumumab11$96,091
CopaxoneGlatiramer Acetate16$91,653
QuliptaAtogepant62$72,262
GlatopaGlatiramer Acetate31$64,801
Glatiramer Acetate32$53,913
Emgality PenGalcanezumab-Gnlm47$34,725
Nurtec OdtRimegepant Sulfate20$21,537
GocovriAmantadine Hcl12$20,196
Aimovig AutoinjectorErenumab-Aooe21$16,247
Ajovy SyringeFremanezumab-Vfrm16$15,200
Rivastigmine39$9,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$244,822$316,202244 claims
Teva Pharmaceuticals USA, Inc.Copaxone$38,938$91,65316 claims
MDD US Operations, LLCGocovri$35$20,19612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 361 neurology providers in Tennessee.

Other neurology in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →